Arabic Arabic English English French French German German

Gene research uncovers promising combination therapy for triple negative breast cancer

Breast cancer is the leading cause of cancer death in women around the world, responsible for 1,700 deaths every day. Although the vast majority of breast cancers are treatable, the most aggressive subtype—triple negative breast cancer (TNBC) – has a high recurrence rate, a high potential for metastasis and shows resistance to conventional treatments, leading to very poor prognosis and survival outcomes. A team of researchers at the Research Institute of the McGill University Health Center (RI-MUHC) conducted a preclinical study and discovered a novel targeted combination therapy that efficiently reduced tumor growth in metastatic breast cancer. Published in Nature Communications, their findings could lead to the development of a novel first line targeted therapy for the treatment of TNBC, with the prospect of rapidly transitioning to clinical trials in humans. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Cell and colony motion index of oral keratinocytes predicts epithelial regenerative capacity

Next Post

New method of gene analysis prevents early death in familial hypercholesterolemia

Related Posts